Published: 20/06/2002, Volume II2, No.5810 Page 8
An alliance of charities for visual disability and blindness has protested at signs that the National Institute for Clinical Excellence could issue guidance which limits the use of photodynamic therapy (Visudyne) to treat agerelated macular degeneration.NICE has pointed out that it has not yet issued any guidance of recommendations on photodynamic therapy, and that the final appraisal determination, published on its website, is open to appeal. July next year would be the earliest that guidance would be available, said NICE. Steve Winyard, chair of the AMD Alliance UK and head of policy at the Royal National Institute for the Blind, said it would be 'outrageous' if the use of photodynamic therapy was restricted to the better-seeing eye or to those who are already blind in one eye, as the final appraisal determination had suggested.
www. nice. org. uk